DEFERRED REVENUE |
9 Months Ended |
---|---|
Dec. 31, 2022 | |
Deferred Revenue | |
DEFERRED REVENUE | NOTE 8. DEFERRED REVENUE
Deferred revenues in the aggregate amount of $35,556 as of December 31, 2022, were comprised of a current component of $13,333 and a long-term component of $22,223. Deferred revenues in the aggregate amount of $45,559 as of March 31, 2022, were comprised of a current component of $13,333 and a long-term component of $32,226. These line items represent the unamortized amounts of a $200,000 advance payment received for a TAGI Pharma (“TAGI”) licensing agreement with a fifteen-year term beginning in . These advance payments were recorded as deferred revenue when received and are earned, on a straight-line basis over the life of the licenses. The current component is equal to the amount of revenue to be earned during the 12-month period immediately subsequent to the balance sheet date and the long-term component is equal to the amount of revenue to be earned thereafter.
|